Can't find the products you're looking for? Try to filter in the left sidebar.Filter By Tag
Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us
For Research Use Only. Not For Clinical Use.
Creative Biolabs supplies excellent and innovative recombinant antibodies specifically targeting CD79B, tailored for biomedical research. We are dedicated to facilitating research and discovery by offering recombinant products that meet the highest standards of quality and performance. Our commitment extends beyond providing exceptional value; we also deliver superb technical support to assist researchers in maximizing their results. By choosing our CD79B antibodies, you gain reliable tools that enhance your investigations and contribute to meaningful advancements in biomedical science.
CD79B is a protein that is part of the B-cell antigen receptor complex. It plays a crucial role in B-cell activation and signaling. In research, understanding CD79B is important as it provides insights into the normal functioning of B cells and immune responses. Dysregulation of CD79B has been implicated in various diseases, particularly B-cell malignancies. Studying CD79B can help in the development of targeted therapies for these disorders. It can also aid in the design of diagnostic tools to detect and monitor B-cell related diseases. Additionally, exploring CD79B may contribute to a better understanding of the immune system and its interactions with other cells and molecules.
CD79b molecule; B29; IGB; AGM6; Igbeta
CD79B (CD79b Molecule) is a Protein Coding gene. Diseases associated with CD79B include Agammaglobulinemia 6, Autosomal Recessive and Agammaglobulinemia, Non-Bruton Type. Among its related pathways are Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers and Innate Immune System. Gene Ontology (GO) annotations related to this gene include transmembrane signaling receptor activity.
We provided high-quality anti-CD79B recombinant antibody products to accelerate biological research and discovery of CD79B target.
Cat. No. | Product Name | Target Species | Host Species | Applications |
TAB-897 | Humanized Anti-CD79B Recombinant Antibody (clone Polatuzumab) | Human | Human | Neut; ELISA; IF; IP; FuncS; FC; ICC |
FAMAB-0058YC | Hamster Anti-Cd79b Recombinant Antibody (clone HM79-16) | Mouse | Hamster | FuncS |
HPAB-0364LY | Human Anti-CD79B Recombinant Antibody | Human | Human | Inhib; ELISA |
HPAB-618-FY | Human Anti-CD79B Recombinant Antibody | Human | Human | FC; ELISA |
HPAB-1491-FY | Human Anti-CD79B Recombinant Antibody (clone P2C2) | Human | Human | ELISA; WB |
To fulfill customer requirements, we have put in place a strict quality management system to guarantee the quality of our products and offer customers high-quality technical services.
Fig.1 SDS-PAGE analysis of anti-CD79B antibody
(Cat# FAMAB-0058YC, Creative Biolabs).
Fig.2 SEC-HPLC analysis of anti-CD79B antibody
(Cat# FAMAB-0058YC, Creative Biolabs).
Fig.3 ELISA analysis of anti-CD79B antibody
(Cat# TAB-897, Creative Biolabs).
Fig.4 WB analysis of anti-CD79B antibody
(Cat# TAB-897, Creative Biolabs).
We possess several years of experience in the production and optimization of recombinant antibodies. By offering the finest quality service, we supply you with recombinant antibody products of high quality and standard in the shortest possible time.
Featured Anti-CD79B Recombinant Antibody Production Platforms
Fig.5 Milligram-scale recombinant antibody production.
Fig.6 Gram-scale recombinant antibody production
Creative Biolabs possesses a variety of high-quality antibody formats to fulfill the diverse demands of customers. The range of antibody formats includes, but is not limited to, full-length, VH, Fab, and scFv, among others.
Fig.7 Full Length Anti-CD79B Recombinant Antibody Production and Modalities
Table 1. Therapeutic approaches targeting CD79B in clinical development.
Research phase | Company | Classification | Indications | Details |
Launched - 2019 | Chugai Pharmaceutical | Drug Conjugates | Chronic lymphocytic leukemia | This is a CD79b-targeted antibody-drug conjugate comprising an anti-CD79b monoclonal antibody and a monomethyl auristatin E (MMAE)-based payload. |
Phase II | Hangzhou Huadong Medicine Group | Biologics | Autoimmune disease | It is a bispecific humanized diabody targeting both CD32B and CD79B, is in phase II development at Provention Bio (now Sanofi) for the treatment of systemic lupus erythematosus. |
Phase I | Janssen | Biologics | Chronic lymphocytic leukemia | This is a T-cell redirecting tri-specific antibody developed by Janssen, is in early clinical development in an injectable subcutaneous formulation for the treatment of B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia. |
Phase I | Genentech | Drug Conjugates | Non-Hodgkin lymphoma | It is an antibody-drug conjugate that has been in phase I clinical trials for the treatment of relapsed or refractory B cell non-Hodgkin's lymphoma; however no recent developments have been reported. |
For more details regarding our anti-CD79B recombinant antibody products, please do not hesitate to contact us. Our knowledgeable team is here to provide assistance and address any inquiries you may have. We look forward to establishing a mutually advantageous partnership that supports your research goals.